{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%3A+Placebo", "query": { "intervention": "Part 1: Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1274, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%3A+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T22:04:15.198Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01967940", "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "Current failing ARV regimen", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-10-25", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 5, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967940" }, { "nct_id": "NCT02665143", "title": "A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Nintedanib and AML induction", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-07-21", "completion_date": "2021-03-30", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Nashville, Tennessee", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665143" }, { "nct_id": "NCT04772885", "title": "A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Atopic Dermatitis", "Hidradenitis Suppurativa" ], "interventions": [ { "name": "KT-474/Placebo", "type": "DRUG" }, { "name": "KT-474", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kymera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 154, "start_date": "2021-02-23", "completion_date": "2022-10-20", "has_results": false, "last_update_posted_date": "2022-10-24", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772885" }, { "nct_id": "NCT02466243", "title": "Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatomyositis" ], "interventions": [ { "name": "JBT-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 22, "start_date": "2015-06", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466243" }, { "nct_id": "NCT04444050", "title": "Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "BMS-986331", "type": "DRUG" }, { "name": "Placebo, Matching BMS-986331", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2020-06-23", "completion_date": "2021-05-19", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 2, "location_summary": "Anaheim, California • Lenexa, Kansas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04444050" }, { "nct_id": "NCT06046443", "title": "A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypothalamic Obesity" ], "interventions": [ { "name": "LB54640", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 28, "start_date": "2024-07-11", "completion_date": "2026-02-09", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 7, "location_summary": "Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06046443" }, { "nct_id": "NCT00000912", "title": "A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 475, "start_date": null, "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 44, "location_summary": "Los Angeles, California • Menlo Park, California • San Diego, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Menlo Park", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000912" }, { "nct_id": "NCT03897088", "title": "Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Scalp Psoriasis" ], "interventions": [ { "name": "PART 1: Double-blind Placebo-controlled", "type": "DRUG" }, { "name": "PART 2: Double-blind Active Treatment Extension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2019-03-29", "completion_date": "2022-02-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 19, "location_summary": "Encinitas, California • Fountain Valley, California • Fremont, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897088" }, { "nct_id": "NCT01133405", "title": "A Safety Study of LY2886721 Single Doses in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "LY2886721", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 40, "start_date": "2010-06", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2019-09-16", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 1, "location_summary": "Beverly Hills, California", "locations": [ { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133405" }, { "nct_id": "NCT05579431", "title": "A Phase 1, First-in-human Study of VX-634", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alpha 1-Antitrypsin Deficiency" ], "interventions": [ { "name": "VX-634", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 127, "start_date": "2022-10-13", "completion_date": "2023-11-13", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-12T22:04:15.198Z", "location_count": 5, "location_summary": "Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579431" } ] }